cerca CERCA
Venerdì 05 Marzo 2021
Aggiornato: 15:19
Temi caldi

been

CGTN: Poverty alleviation, a solemn promise fulfilled by Chinese leadership

BEIJING, Feb. 22, 2021 /PRNewswire/ -- With its fundamental purpose of serving the people heart and soul, the Communist Party of China (CPC) has been devoted to leading the nation towards building a moderately prosperous society in all respects, and has helped it achieve miraculous results in reducing poverty.

Octapharma AG: Final data from the NuProtect study published on the immunogenicity of Nuwiq® in previously untreated patients with severe haemophilia A

LACHEN, Switzerland, Feb. 22, 2021 /PRNewswire/ -- Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. "Simoctocog Alfa (Nuwiq®) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study" https://www.thieme-connect.com/products/ejournals/abstra...

12-Month Below-the-Knee Data with MedAlliance's SELUTION SLR™ Presented as Late Breaking Trial at LINC

NYON, Switzerland, Jan. 28, 2021 /PRNewswire/ -- 12-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a Late Breaking Trial at LINC 2021. The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, for the treatment of long tibial occlusive lesions (TASC C & D) in patients with Critical Limb Ischemia (CLI).

ora in
Prima pagina
articoli
in Evidenza